Browse by author
Lookup NU author(s): Dr Ruth Norris, Sue Thompson, Philip Mawson, Mark Turner, Henry Cain, Dr Guy TaylorORCiD, Professor Linda SharpORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Copyright © 2025. Published by Elsevier Ltd.Purpose Women with estrogen receptor-positive breast cancer are recommended daily oral adjuvant endocrine therapy for at least 5 years, but up to 50 % discontinue early. We assessed an evidence-based, theoretically-informed, patient-centred intervention (HT&Me) to support adjuvant endocrine therapy adherence and improve quality-of-life, in terms of patient acceptability and feasibility to deliver within the UK National Health Service. Methods This single arm study aimed to recruit 45 women with stage I-III breast cancer within 14 weeks of first adjuvant endocrine therapy prescription. After completing baseline questionnaires, participants received the HT&Me intervention comprising: (i) a short animation; (ii) two personalised nurse/practitioner consultations (in-person or online); (iii) an interactive web-app; and (iv) regular email reminders. Participants completed follow-up questionnaires at 8 weeks. A sub-sample of participants (n = 20) and health professionals (n = 14) participated in semi-structured interviews. Results We recruited 51 participants. Participants varied in digital confidence at recruitment (low/moderate, 28 % (n = 14); high, 61 % (n = 31)). HT&Me was demonstrated as feasible to deliver. Overall, 69 % (n = 35) engaged with the web-app; 87 % (n = 40/46) found HT&Me helpful; and 80 % (n = 36/45) reported it motivated them to keep taking endocrine therapy. Both consultation formats were considered acceptable. Completion of outcome measures was high. Health professionals considered HT&Me addresses an important unmet need. Conclusions HT&Me is feasible, acceptable and helpful to women. Findings provided valuable insights for design and delivery of the full-scale randomised controlled trial assessing effectiveness now underway (ISRCTN24852890). HT&Me offers potential to improve adjuvant endocrine therapy adherence, thereby reducing recurrence risk for women with estrogen receptor positive breast cancer. Study registration ISRCTN number ISRCTN29401613
Author(s): McGeagh L, Stewart S-J, Norris R, Wells M, Thompson S, Mawson P, Brett J, Turner M, Wolstenholme J, Dakin H, Donnelly P, Cain H, Rehman F, Kum S, Horne R, Taylor G, Turner L, Rose J, Sharp L, Watson E
Publication type: Article
Publication status: Published
Journal: European Journal of Oncology Nursing
Year: 2026
Volume: 80
Pages: epub ahead of print
Online publication date: 01/11/2025
Acceptance date: 28/10/2025
ISSN (print): 1462-3889
ISSN (electronic): 1532-2122
Publisher: Churchill Livingstone
URL: https://doi.org/10.1016/j.ejon.2025.103026
DOI: 10.1016/j.ejon.2025.103026
Altmetrics provided by Altmetric
